齐拉西酮与氯氮平治疗精神分裂症对照研究

A comparative study of ziprasidone and clozapine in treatment of schizophrenia

目的:探讨齐拉西酮治疗精神分裂症的疗效和不良反应。方法:将60例符合中国精神障碍分类与诊断标准第3版的精神分裂症患者,随机分为齐拉西酮组和氯氮平组,疗程6周,用阳性与阴性症状量表(PANSS)评定疗效,用治疗中出现的症状量表(TESS)观察不良反应,分别于治疗前、治疗2周、治疗4周评定1次。结果:两组疗效差异无显著性(P>0.05),齐拉西酮不良反应显著少于氯氮平。结论:齐拉西酮对精神分裂症的疗效与氯氮平相当,不良反应较小,服药依从好,可作为分裂症的首选药物。

Objective： To explore the efficacy anti safety of ziprasidone in the treatment of schizophrenia. Method：Sixty schizophrenia patients who met with the diagnostic criteria of CCMD-3 were randomly assigned to ziprasidone group or clozapine group and then received 6 weeks treatment. The efficacy and side effects were evaluated with the positive and negative symtom scale（PANSS） and treatment emergent symptoms scale（TESS） before and at the end of 2nd ,4th and 6th weeks trealment. Results： No significant difference was found in the efficacy between two groups,but the side effects were significantly less in ziprasidone group than in clozapine group. Condusion：Ziprasidone has similar efficacy with clozapine ,with mild side effects and better compliance,and it can be recommended as one of first-line drugs in the treatment of schizophrenia.